GLP-1s are shrinking bodies. Enter cadaver fat injections

Key Points:

• AlloClae is a new injectable body contouring product made from fat harvested from donated cadavers, offering a non-surgical alternative to traditional fat grafting with minimal downtime and quick administration.
• Since its US release in 2024, over 2,000 patients have used alloClae, especially appealing to those on weight-loss medications like Ozempic who want to restore volume in targeted areas such as breasts and buttocks.
• The product raises ethical concerns due to the use of cadaver fat, limited federal regulation of body donation for cosmetic purposes, and debates over donor consent and commercialization of donated bodies.
• Some patients have reported complications like fat necrosis, though manufacturers claim no confirmed cases of rejection or infection; experts call for more clinical trials to assess long-term safety and efficacy.
• Industry leaders compare alloClae’s potential impact to that of Botox, viewing it as part of a broader trend toward normalized cosmetic enhancements that support mental well-being and self-confidence.